Overview

SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis

Status:
Completed
Trial end date:
2020-02-05
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of treatment with SK-1403 for 52 weeks in patients with secondary hyperparathyroidism on maintenance hemodialysis.
Phase:
Phase 3
Details
Lead Sponsor:
Sanwa Kagaku Kenkyusho Co., Ltd.